During the last session, Elevation Oncology Inc (NASDAQ:ELEV)’s traded shares were 1.23 million, with the beta value of the company hitting 1.49. At the end of the trading day, the stock’s price was $3.64, reflecting an intraday loss of -6.06% or -$0.24. The 52-week high for the ELEV share is $5.89, that puts it down -61.81 from that peak though still a striking 90.11% gain since the share price plummeted to a 52-week low of $0.36. The company’s market capitalization is $177.33M, and the average trade volume was 1.18 million shares over the past three months.
Elevation Oncology Inc (NASDAQ:ELEV) trade information
Elevation Oncology Inc (ELEV) registered a -6.06% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -6.06% in intraday trading to $3.64, hitting a weekly high. The stock’s 5-day price performance is -9.10%, and it has moved by -27.10% in 30 days. Based on these gigs, the overall price performance for the year is 113.16%.
Elevation Oncology Inc (ELEV) estimates and forecasts
Statistics show that Elevation Oncology Inc has outperformed its competitors in share price, compared to the industry in which it operates. Elevation Oncology Inc (ELEV) shares have gone up 507.60% during the last six months, with a year-to-date growth rate more than the industry average at 35.07% against 12.90.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -52.56%. While earnings are projected to return 36.27% in 2024.
ELEV Dividends
Elevation Oncology Inc is due to release its next quarterly earnings in May. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
